Geneos Wealth Management’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Geneos Wealth Management’s Portfolio BTAL Stock Details BTAL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.1K	Buy	2,250 +2,000	+800%	+$24.3K	﹤0.01%	1718
2026 Q1	$3.49K	Hold	250	–	–	﹤0.01%	2227
2025 Q4	$3.6K	Buy	+250	New	+$3.76K	﹤0.01%	2220
2025 Q2	–	Sell	-1,247	Closed	-$26K	–	3120
2025 Q1	$26K	Buy	+1,247	New	+$23.6K	﹤0.01%	1814
2024 Q4	–	Sell	-35,150	Closed	-$689K	–	2890
2024 Q3	$689K	Buy	35,150 +1,600	+5%	+$31.8K	0.03%	482
2024 Q2	$658K	Sell	33,550 -10,200	-23%	-$194K	0.03%	434
2024 Q1	$788K	Buy	43,750 +2,364	+6%	+$42.9K	0.04%	395
2023 Q4	$701K	Buy	41,386 +3,249	+9%	+$64.6K	0.03%	396
2023 Q3	$757K	Buy	38,137 +21,187	+125%	+$401K	0.04%	371
2023 Q2	$318K	Sell	16,950 -2,052	-11%	-$41.4K	0.02%	573
2023 Q1	$388K	Buy	19,002 +15,983	+529%	+$322K	0.02%	494
2022 Q4	$64K	Buy	+3,019	New	+$62.6K	﹤0.01%	959

Other funds holding BTAL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

CCA

Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

AWM

AE Wealth Management Topeka, Kansas $21.5B AUM 26.98% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $62.3B AUM 44.64% 1-Year Est. Return

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

Geneos Wealth Management's BTAL Position: Q2 2026 in Review

Geneos Wealth Management increased its AGF US Market Neutral Anti-Beta Fund (BTAL) stake by 800% in Q2 2026, buying an estimated $24.3K and bringing the position to 2,250 shares worth $25.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

Geneos Wealth Management first reported a position in BTAL in Q4 2022 and has held it in 12 quarters since. The position peaked at $788K in Q1 2024. 93 funds tracked by Wall St. Rank hold BTAL as of Q2 2026.

Geneos Wealth Management held 2,250 shares of AGF US Market Neutral Anti-Beta Fund worth $25.1K as of Q2 2026.
Geneos Wealth Management bought 2,000 AGF US Market Neutral Anti-Beta Fund shares in Q2 2026, an estimated $24.3K.
AGF US Market Neutral Anti-Beta Fund made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1718 holding.
Geneos Wealth Management first reported a position in AGF US Market Neutral Anti-Beta Fund in Q4 2022 and has held it in 12 quarters since.
Geneos Wealth Management's AGF US Market Neutral Anti-Beta Fund position peaked at $788K in Q1 2024.
93 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.